MNKD
NASDAQ · Biotechnology
Mannkind Corp
$3.92
+0.16 (+4.26%)
Financial Highlights (FY 2026)
Revenue
342.65M
Net Income
5.77M
Gross Margin
77.8%
Profit Margin
1.7%
Rev Growth
+51.8%
D/E Ratio
1.64
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 77.8% | 77.8% | 47.0% | 47.0% |
| Operating Margin | 11.1% | 10.0% | -25.8% | -21.1% |
| Profit Margin | 1.7% | 1.6% | -19.9% | -16.4% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 342.65M | 225.76M | 248.98M | 263.31M |
| Gross Profit | 266.48M | 175.57M | 117.00M | 123.74M |
| Operating Income | 38.10M | 22.59M | -64,171,609 | -55,597,939 |
| Net Income | 5.77M | 3.42M | -49,454,944 | -43,135,624 |
| Gross Margin | 77.8% | 77.8% | 47.0% | 47.0% |
| Operating Margin | 11.1% | 10.0% | -25.8% | -21.1% |
| Profit Margin | 1.7% | 1.6% | -19.9% | -16.4% |
| Rev Growth | +51.8% | +51.8% | +22.2% | -0.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 375.64M | 375.64M | 706.23M | 797.53M |
| Total Equity | 228.87M | 228.87M | 703.11M | 611.05M |
| D/E Ratio | 1.64 | 1.64 | 1.00 | 1.31 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 42.01M | 26.29M | -82,218,351 | -89,868,366 |
| Free Cash Flow | — | — | -29,596,680 | -36,846,394 |